109 results
To determine the accuracy of the URIKA urinary bladder sensor in measuring the distance between the anterior - and posterior wall of the bladder and to determine the range in bladder diameters at which the child should be alarmed to void.
- To evaluate the bladder-preservation rate after chemoradiation - To evaluate the toxicity and complications of treatment with induction chemotherapy followed by ePLND and chemoradiation
Primary objective *To evaluate the efficacy of 2 dose combinations of solifenacin and mirabegron compared to solifenacin and mirabegron monotherapySecondary objectives*To evaluate the efficacy of 2 dose combinations of solifenacin and mirabegron…
Primary Objective: Is the detection chance of the bladder influenced by the angle in which the ultrasound sensor is fixated? Secondary Objective Can the URIKA Bladder Monitor (UBM) be used to predict the point where the BladderScan reaches the…
Is the day alarm a usefull tool for parents and children to gain more insight in there urine incontinence. By getting a signal at the moment of wetting, parents and children can be trained in a more efficient way to gain more control of their…
In this study, the aim is to perform a clinical evaluation of the NovioMini in children during behavioural bladder training to examine the performance of the NovioMini as a full-bladder-based notification system during natural bladder filling.
The aim is to determine the immediate effect of sacral neuromodulation on urodynamic measurements.
To evaluate BlueWind Medical RENOVATM System safety and performance in OAB patients for extended FU period of 36 months.
Objective: The principal objective is To evaluate the long-term safety and maintenance of efficacy of BOTOX® (200 U) injected into the detrusor for the treatment of urinary incontinence caused by neurogenic detrusor overactivity in patients who have…
To evaluate the safety and efficacy of solifenacin succinate suspension once daily in children and adolescents with OAB.
The primary objective of this Phase II study is to evaluate the clinical efficacy in terms of Disease Free Survival of recMAGE-A3 + AS 15 ASCIversus placebo in the overall population.Secondary objectives are:• To evaluate overall survival in the…
Evaluation of the accuracy of the sentinel node procedure in bladder cancer patients.
The objective of the study is to analyse flow pattern, especially individual variation, and the extend of voiding symtoms in young females and
Subjects randomized to the placebo treatment are unlikely to benefit from the study. However, OAB is not a life-threatening disease and it is not expected that a 12 to 15 week exposure to placebo treatment will have a negative impact on disease…
Increasing diuresis rate in patients with Overactive Bladder symptom complex as a possible treatment
1) Is the difference in diuresis between patients and volunteers caused by a dept in water household in patients and if so can we increase the diuresis in patients by correcting this?2) Can we influence the pattern of bladder sensations by…
The objective of the study is to measure the extend of voiding symptoms and bother of the urinary tract in young females and to analyse flow patterns and post void residual.
The primary objective of this study is to evaluate whether preventive intravesical instillations with 0.2% chondroitin sulphate solution reduce bother related to acute radiation cystitis symptoms patients undergoing pelvic radiotherapy.
The purpose of this trial is to demonstrate the superior efficacy of pudendal neuromodulation in treating patients with neurogenic overactive bladder, who have failed conservative treatment, in a randomized cross-over trial.Symptoms of urinary…
MAIN: To study the influence of increasing diuresis rate on sensation development in patients with OAB complaints. SECONDARY:To study changes in sensory complaints induced by increasing diuresis rate in patients with OAB complaints. If the…
The primary objectives are the following:- To assess the safety profile and determine the Optimal Biological Dose (OBD) or Maximum Tolerated Dose (MTD), whichever occurs first, of intravesically administered TMX-101. The secondary objectives are the…